Zhigang Han

机构：Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University

发表论文 23 篇 · 总被引 3593 次 · h-index 15

代表论文

• Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial (2019 · The Lancet · 被引 2268)
• Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial (2020 · The Lancet Oncology · 被引 704)
• Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study (2021 · The Lancet Respiratory Medicine · 被引 207)
• Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study (2023 · The Lancet Respiratory Medicine · 被引 75)
• Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial (2023 · The Lancet Respiratory Medicine · 被引 68)
• Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). (2020 · Journal of Clinical Oncology · 被引 67)